Geographic distribution of mating type alleles of Cryptococcus neoformans in four areas of the United States

Author(s): Yan Z, Li X, Xu J

Abstract

To better understand the epidemiology and population structure of Cryptococcus neoformans, we determined mating types for 358 C. neoformans strains isolated through the active surveillance program from 1992 to 1994 in four geographic areas in the United States: San Francisco, California; Georgia; Texas; and Alabama. Two assays were used to determine mating types: (i) crossing with standard laboratory tester strains JEC20 and JEC21 on V8 agar medium; and (ii) PCR with the mating type alpha allele-specific primer of the STE12 gene and with serotype (A and D)- and mating type (a and alpha)-specific primers of the STE20 gene. Using these two methods, we found that this sample consisted of the following: (i) 324 serotype A, mating type (MAT) alpha (Aalpha) strains; (ii) 12 serotype D, alpha (Dalpha) strains; (iii) 14 serotype AD strains with mating type alleles Aa and Dalpha (AaDalpha); (iv) 2 serotype AD strains with mating type alleles Aalpha and Da (AalphaDa); (v) 3 serotype B, alpha (Balpha) strains; and (vi) 3 serotype AD strains but with only one mating type allele. No strain with MATa was found within serotype A, B, or D in this collection. Interestingly, 14 of the 19 serotype AD strains contained the Aa allele at the STE20 locus; 13 of these 14 were from San Francisco. Our results suggest that the environment in San Francisco might contain Aa strains capable of mating with Dalpha strains. In addition, our result demonstrate that the sample from San Francisco had a significantly higher proportion of self-fertile strains than those from the other three areas.

Similar Articles

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Author(s): Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al.

Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections

Author(s): Hamza OJ, van den Bout-van den Beukel CJ, Matee MI, Moshi MJ, Mikx FH, et al.

Practice guidelines for the management of cryptococcal disease

Author(s): Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, et al.

The ecology of Cryptococcus neoformans

Author(s): Ellis D, Pfeiffer T

Cryptococcal disease and HIV infection

Author(s): Waters L, Nelson M

Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy

Author(s): Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, et al.

Cryptococcal meningitis

Author(s): Bicanic T, Harrison TS

Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy

Author(s): Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, et al.

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans

Author(s): Venkateswarlu K, Taylor M, Manning NJ, Rinaldi MG, Kelly SL

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans

Author(s): Joseph-Horne T, Hollomon D, Loeffler RS, Kelly SL

In vitro antifungal susceptibility of Cryptococcus gattii

Author(s): Trilles L, Fernández-Torres B, LazéraMdos S, Wanke B, Guarro J

Molecular typing of IberoAmerican Cryptococcus neoformans isolates

Author(s): Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E; IberoAmericanCryptococcal Study Group